Short-Term Treatment with Zanamivir to Prevent Influenza: Results of a Placebo-Controlled Study
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
We explored the prophylactic activity of zanamivir after presumed exposure to influenza in the community. After close contacts with index cases of influenza-like illnesses, 575 subjects were randomized in 4 treatment groups: 144 received placebo, 141 received intranasal zanamivir, 144 received inhaled zanamivir, and 146 received inhaled plus intranasal zanamivir for 5 days. Of 25 subjects (4%) who developed symptomatic influenza during the 5 days of prophylaxis, 9 (36%) were in the placebo group, 8 (32%) were in the intranasal zanamivir group (odds ratio [OR], 0.90; 95% confidence interval [CI], 0.30-2.72; P=.855), 3 (12%) were in the inhaled zanamivir group (OR, 0.27; 95% CI, 0.07-1.05; P=.058), and 5 (20%) were in the inhaled plus intranasal zanamivir group (OR, 0.52; 95% CI, 0.17-1.58; P=.247). Short-term treatment with intranasal zanamivir was ineffective. However, inhaled zanamivir treatment reduced the rate of influenza, which was 2%-3% among zanamivir recipients versus 6% among placebo recipients. Additional studies assessing a longer duration of postcontact prophylaxis are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hayden, F. G., Osterhaus, A. D. M. E., Treanor, J. J., Fleming, D. M., Aoki, F. Y., Nicholson, K. G., Bohnen, A. M., Hirst, H. M., Keene, O., & Wightman, K. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709253371302 · Cited by 762
Self-citationUse of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent Influenza
Hayden, F. G., Atmar, R. L., Schilling, M., Johnson, C., Poretz, D., Paar, D., Huson, L., Ward, P., & Mills, R. G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910283411802 · Cited by 512
Self-citation(1998) · The Lancet · doi:10.1016/s0140-6736(98)10190-3 · Cited by 351
Zanamivir in the Prevention of Influenza Among Healthy Adults: A Randomized Controlled Trial
Monto, A. S., Robinson, D. P., Herlocher, M. L., Hinson, Jr., Elliott, M. J., & Crisp, A. (1999) · JAMA · doi:10.1001/jama.282.1.31 · Cited by 321
Cited by
Review of Aerosol Transmission of Influenza A virus
Tellier, R. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1211.060426 · Cited by 803
“infection, intranasally applied zanamivir was not protective (22), whereas inhaled zanamivir was protective in one study (23) and a protective effect approached statistical significance in another study (22).”
BackgroundInfluentialUyeki, T. M., Bernstein, H. H., Bradley, J. S., Englund, J. A., File, T. M., Fry, A. M., Gravenstein, S., Hayden, F. G., Harper, S. A., Hirshon, J. M., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy866 · Cited by 795
Self-citationInfluenza virus neuraminidase inhibitors
Gubareva, L. V., Kaiser, L., & Hayden, F. G. (2000) · The Lancet · doi:10.1016/s0140-6736(99)11433-8 · Cited by 730
Self-citationNicholson, K. G., Wood, J. M., & Zambon, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14854-4 · Cited by 691
Transmission routes of respiratory viruses among humans
Kutter, J. S., Spronken, M. I., Fraaij, P. L., Fouchier, R. A., & Herfst, S. (2018) · Current Opinion in Virology · doi:10.1016/j.coviro.2018.01.001 · Cited by 611
Metadata
- Authors
- Kaiser, L., Henry, D., Flack, N. P., Keene, O., & Hayden, F. G.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-03-01
- Volume
- 30
- Issue
- 3
- Pages
- 587-589
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2125041961
- Cited by
- 84
- References
- 4
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Short-Term Treatment with Zanamivir to Prevent Influenza: Results of a Placebo-Controlled Study. https://app.cochat.ai/papers/10.1086/313696
- The paper
- Kaiser, L., Henry, D., Flack, N. P., Keene, O., & Hayden, F. G. (2000). Short-Term Treatment with Zanamivir to Prevent Influenza: Results of a Placebo-Controlled Study. Clinical Infectious Diseases. https://doi.org/10.1086/313696
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.